Cited by 580Inflammatory Bowel DiseaseGut microbiota and healthGastrointestinal motility and disorders

Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model

Open access
Chen, Guangxin, Ran, Xin, Li, Bai, Li, Yuhang, He, Dewei, Huang, Bingxu, Fu, Shoupeng, Liu, Juxiong +1 more·2018·eBioMedicine

Abstract

G Protein Coupled Receptor 109A (GPR109A), which belongs to the G protein coupled receptor family, can be activated by niacin, butyrate, and β-hydroxybutyric acid. Here, we assessed the anti-inflammatory activity of sodium butyrate (SB) on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mice, an experimental model that resembles Crohn's disease, and explored the potential mechanism of SB in inflammatory bowel disease (IBD). In vivo , experimental GPR109a −/− and wild-type ( WT ) mice were administered SB (5g/L) in their drinking water for 6weeks. The mice were then administered TNBS via rectal perfusion to imitate colitis. In vitro , RAW246.7 macrophages, Caco-2 cells, and primary peritoneal macrophages were used to investigate the protective roles of SB on lipopolysaccharide (LPS)-induced inflammatory response and epithelium barrier dysfunction. In vivo , SB significantly ameliorated the inflammatory response and intestinal epithelium barrier dysfunction in TNBS-induced WT mice, but failed to provide a protective effect in TNBS-induced GPR109a −/− mice. In vitro , pre-treatment with SB dramatically inhibited the expression of TNF-α and IL-6 in LPS-induced RAW246.7 macrophages. SB inhibited the LPS-induced phosphorylation of the NF-κB p65 and AKT signaling pathways, but failed to inhibit the phosphorylation of the MAPK signaling pathway. Our data indicated that SB ameliorated the TNBS-induced inflammatory response and intestinal epithelium barrier dysfunction through activating GPR109A and inhibiting the AKT and NF-κB p65 signaling pathways. These findings therefore extend the understanding of GPR109A receptor function and provide a new theoretical basis for treatment of IBD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2018.03.030

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chen, G., Ran, X., Li, B., Li, Y., He, D., Huang, B., Fu, S., Liu, J., & Wang, W.
Affiliations
  • Jilin University (CN)
  • First Hospital of Jilin University (CN)
Corresponding author
  • Liu, Juxiong
  • Wang, Wei
Venue
eBioMedicine
Publisher
Elsevier BV
Published
2018-04
Volume
30
Pages
317-325
ISSN
2352-3964 (ISSN-L)
OpenAlex
W2794833162
Cited by
580
References
54
Citations by year
2026: 69 · 2025: 102 · 2024: 108 · 2023: 95 · 2022: 75 · 2021: 64 · 2020: 38 · 2019: 21 · 2018: 7
FWCI
19.89
Type
journal article
Language
en
Open access
Locations
  • EBioMedicine (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Jilin University
  • National Aerospace Science Foundation of China
  • Graduate Student's Research and Innovation Fund of Sichuan University (2017168)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
sodium butyrate, GPR109A, inflammatory bowel disease, TNBS-induced colitis, Crohn's disease, intestinal epithelial barrier, NF-κB p65 signaling, Akt signaling, lipopolysaccharide-induced inflammation, macrophages, Caco-2 cells, anti-inflammatory activity
MeSH terms
RAW 264.7 Cells, Animals, Colon, Disease Models, Animal, Epithelium, Humans, Inflammation, Lipopolysaccharides, Mice, Inbred C57BL, Permeability, Phosphorylation, Trinitrobenzenesulfonic Acid, Inflammatory Bowel Diseases, Signal Transduction, Weight Loss, Survival Analysis, Cytokines, Macrophages, Peritoneal, Caco-2 Cells, Tight Junctions, Butyric Acid, Proto-Oncogene Proteins c-akt, Mice, Transcription Factor RelA, Mucin-2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review